Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients with Bipolar Depression

Study identifier:5077US/0049

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

-

Medical condition

Bipolar Disorder

Phase

Phase 3

Healthy volunteers

No

Study drug

SEROQUEL (quetiapine fumarate) Tablets

Sex

All

Actual Enrollment

-

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Sept 2002
Primary Completion Date: 01 Sept 2003
Study Completion Date: 01 Sept 2003

Study design

Allocation: None
Endpoint Classification: None
Intervention Model: None
Masking: None
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria